2 Drugmakers Seek To End Trials Of Merck's Antiviral Drug For Covid.

2 Drugmakers Seek To End Trials Of Merck's Antiviral Drug For Covid

Merck has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir (File)

Bengaluru:

Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.

The two drugmakers, Aurobindo Pharma Ltd and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-19, the drug regulator's expert committee said on Friday.

The two companies separately sought permission to end trials in the case of moderate COVID-19 patients after having submitted interim clinical trial data around the effectiveness of the drug in treating this category of patients, the committee disclosed, throwing into question the efficacy of the experimental drug in improving outcomes for patients with moderate cases of COVID-19.

Separately, a source at the drug regulator told Reuters that molnupiravir had shown no "significant efficacy" against moderate COVID-19 cases

Shares in Merck soared last week after it and partner Ridgeback Biotherapeutics said an interim analysis of a late-stage clinical trial on molnupiravir showed the medicine nearly halved the risk of hospitalisation or death for patients with mild or moderate COVID-19.

It was not immediately clear whether the drugmakers and Merck used identical criteria to define moderate COVID-19 cases.

Aurobindo Pharma, MSN and Merck did not immediately reply to Reuters' requests for comment.

Merck has entered into voluntary licensing agreements with at least eight Indian drugmakers for molnupiravir, with an aim to turn the country into a manufacturing hub for the drug to supply low- and middle-income nations.

Aurobindo Pharma has been conducting a clinical trial on the drug in 100 patients with moderate COVID-19 since August this year

According to its trial details, moderate patients included those with fever, coughing, breathing difficulties and oxygen deficiency.

Of the eight Indian firms, five - Dr Reddy's Laboratories, Cipla, Sun Pharma, Torrent Pharmaceuticals and Emcure Pharmaceuticals - are conducting a joint trial for the antiviral drug only in mild COVID-19 patients in an outpatient setting

The other licenced company, Hetero, in early July announced interim data from its own late-stage trial in treating mild COVID-19 patients and submitted an application for emergency use approval for the same

Hetero is separately conducting a study on moderate COVID-19 patients and it has said clinical results on the same will be shared in due course

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news
Jimmy Failla and Johnny Joey Jones recount the life of Colin Powell - Fox Across America.

Jimmy Failla and Johnny Joey Jones recount the life of Colin Powell - Fox Across America.

On Fox Across America with Jimmy Failla, Fox News Contributor and Podcast Host Johnny Joey Jones talk about the legacy of Gen. Colin Powell & why so many Americans are rebelling against vaccine mandates.

Officials Say ‘No One Intervened’ As Woman Was Assaulted On Pennsylvania Train.

Officials Say ‘No One Intervened’ As Woman Was Assaulted On Pennsylvania Train.

Police say a woman was raped on a Pennsylvania train as passengers watched, and no one intervened or called for help. A 35-year-old man is facing rape and assault charges.  » Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a col...

What can business learn from nature?

What can business learn from nature?

This series, produced by Sky Media in collaboration with PwC , looks at how businesses can find inspiration in some unexpected places, and why many of their biggest challenges will be Better Solved Together. Hosted by Angellica Bell, this episode ...

2 1

East vs. West coast disputes within hip-hop genre, loss of music icons: Part 3

East vs. West coast disputes within hip-hop genre, loss of music icons: Part 3

The hip-hop community was left reeling after the death of legends Biggie Smalls and Tupac Shakur. Women like Missy Elliott and Lauryn Hill stepped up to help heal and fill the talent void.

Hip-hop becomes seen as a credible music genre with widespread appeal: Part 2.

Hip-hop becomes seen as a credible music genre with widespread appeal: Part 2.

Faced with a growing trend toward misogynistic lyrics in rap in the 1990s, female MC's held their ground by responding with empowering messaging. Queen Latifah became a model for female empowerment.

'Mother of the Mic' MC Sha-Rock helped pioneer women in hip-hop: Part 1.

'Mother of the Mic' MC Sha-Rock helped pioneer women in hip-hop: Part 1.

In the late 1970s and early 80s, women played a foundational role in hip-hop. MC Sha-Rock earned a spot with the "Funky Four Plus One," making her one of hip-hop's first female MC's.